Aura Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
AURA$7.65-0.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months EndedMarch 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Operating Expenses: | ||
| Research and development | $27,960 | $23,343 |
| General and administrative | 6,906 | 5,692 |
| Total operating expenses | 34,866 | 29,035 |
| Total operating loss | (34,866) | (29,035) |
| Other income (expense): | ||
| Interest income, including amortization and accretion income | 1,190 | 1,594 |
| Other income (expense) | 2 | (24) |
| Total other income | 1,192 | 1,570 |
| Loss before income taxes | (33,674) | (27,465) |
| Income tax provision, net | (11) | (18) |
| Net loss | $(33,685) | $(27,483) |
| Net loss per common share—basic and diluted | $(0.50) | $(0.55) |
| Weighted average common stock outstanding—basic and diluted | 67,447,576 | 50,126,148 |
| Comprehensive loss: | ||
| Net loss | $(33,685) | $(27,483) |
| Other comprehensive income (loss): | ||
| Unrealized loss on marketable securities | (78) | (137) |
| Currency translation adjustment | (27) | (21) |
| Total other comprehensive loss | (105) | (158) |
| Total comprehensive loss | $(33,790) | $(27,641) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.